Peregrine Ventures Overview
Peregrine Ventures is an Israeli healthcare fund that strategically set up to provide each portfolio company the support it needs at every stage of a company’s lifecycle. Peregrine’s investment vehicles include early and mid-stage funds, Peregrine’s ‘Incentive’ Incubator, and Peregrine Growth, a fund dedicated to more mature companies in their last rounds of financing prior to an M&A or IPO.
Latest News
growth-positive
"Global medical device companies are actively scouting Israeli startups—many of which are founded by alumni of those same corporations—as they search for future growth engines," writes Eyal Lifschitz, Managing Partner at Peregrine Ventures.
The article highlights the significant role of Israeli startups in the global medical device industry, emphasizing their innovation and impact on healthcare. Israeli entrepreneurs, often alumni of global corporations, are key drivers of this success. These startups are known for their rapid development and adherence to high standards, making them attractive to global corporations seeking new growth engines. Companies like Medtronic and Johnson & Johnson have established R&D centers in Israel, recognizing the quality of Israeli human capital. Despite challenges, Israeli startups continue to thrive, with notable exits and IPOs in the medical device sector. The article underscores the synergy between Israeli innovation and American corporate standards, positioning Israel as a leader in medical technology.
InvestmentAcquisitionPartners
growth-positive
Biomed company CartiHeal acquired by Smith & Nephew for up to $330 million | CTech
Israeli biomed company CartiHeal, which develops a coral-based implant for damaged joints, is being acquired by Smith & Nephew (S&N) for up to $330 million. The deal includes an initial cash consideration of $180 million, with a further $150 million contingent on financial performance. The acquisition is expected to close in the first quarter of 2024. CartiHeals investors are expected to see an average return of up to 6 times, depending on the final agreement value. The companys CEO, Nir Altschuler, will continue as a consultant for six months after the deal closes, and all CartiHeal employees are expected to continue working under S&N.
AcquisitionInvestment
growth-positive
Peregrine Ventures announces new consortium to invest over $90 million in medical startups | CTech
Peregrine Ventures, a healthcare-focused investment firm, has announced the formation of a consortium of leading companies and research institutes to join its Incentive Technology Incubator. The new members include Bristol-Myers Squibb, BD, Elbit Systems, and institutions such as Tel Aviv University, Ben-Gurion University of the Negev, and Shaare Zedek Medical Center. The consortium will jointly develop and invest over $90 million in startups and graduates of Peregrine’s technology incubator. The incubator has been instrumental in developing new ventures and supporting pre-seed, seed, and early-stage investments.
InvestmentPartners
growth-positive
China's Venus Medtech buys Israeli co Cardiovalve
Chinese structural heart disease treatment company, Venus Medtech, has agreed to acquire Israeli heart valve treatment company, Cardiovalve, for $300 million. The deal includes an immediate payment of $150 million and a further $150 million contingent on regulatory milestones. Venus Medtech has also committed to invest an additional $100 million in Cardiovalve. Cardiovalve was founded in 2010 by Amir Gross, who will continue to lead the companys innovation under Venus Medtech.
AcquisitionInvestment
Israel's Peregrine Ventures raises $115 million for new med-tech fund
Team Members
8
Web & Social Links
| Website | www.peregrinevc.com/ |
Locations
Yoni Netanyahu St 6, Or Yehuda, Israel
Photos & Videos
1 item(s)
Peregrine Ventures Business
Business models
—
Product stage
—
Employees
—
Sector
—Target Customer
—Core Technology
—Tags (8)
pharmaceuticalshealthcarevascularroboticsvalvesoncologymedical-devicesbiotechnologyPeregrine Ventures Financials
—
Total funding
—
Capital raised
—
Last funding
—
Funding stage
—
Total rounds
—
Investors
Peregrine Ventures Lifecycle
Peregrine Ventures News
6 articles
growth-positive
"Global medical device companies are actively scouting Israeli startups—many of which are founded by alumni of those same corporations—as they search for future growth engines," writes Eyal Lifschitz, Managing Partner at Peregrine Ventures.
The article highlights the significant role of Israeli startups in the global medical device industry, emphasizing their innovation and impact on healthcare. Israeli entrepreneurs, often alumni of global corporations, are key drivers of this success. These startups are known for their rapid development and adherence to high standards, making them attractive to global corporations seeking new growth engines. Companies like Medtronic and Johnson & Johnson have established R&D centers in Israel, recognizing the quality of Israeli human capital. Despite challenges, Israeli startups continue to thrive, with notable exits and IPOs in the medical device sector. The article underscores the synergy between Israeli innovation and American corporate standards, positioning Israel as a leader in medical technology.
InvestmentAcquisitionPartners
growth-positive
Biomed company CartiHeal acquired by Smith & Nephew for up to $330 million | CTech
Israeli biomed company CartiHeal, which develops a coral-based implant for damaged joints, is being acquired by Smith & Nephew (S&N) for up to $330 million. The deal includes an initial cash consideration of $180 million, with a further $150 million contingent on financial performance. The acquisition is expected to close in the first quarter of 2024. CartiHeals investors are expected to see an average return of up to 6 times, depending on the final agreement value. The companys CEO, Nir Altschuler, will continue as a consultant for six months after the deal closes, and all CartiHeal employees are expected to continue working under S&N.
AcquisitionInvestment
growth-positive
Peregrine Ventures announces new consortium to invest over $90 million in medical startups | CTech
Peregrine Ventures, a healthcare-focused investment firm, has announced the formation of a consortium of leading companies and research institutes to join its Incentive Technology Incubator. The new members include Bristol-Myers Squibb, BD, Elbit Systems, and institutions such as Tel Aviv University, Ben-Gurion University of the Negev, and Shaare Zedek Medical Center. The consortium will jointly develop and invest over $90 million in startups and graduates of Peregrine’s technology incubator. The incubator has been instrumental in developing new ventures and supporting pre-seed, seed, and early-stage investments.
InvestmentPartners
growth-positive
China's Venus Medtech buys Israeli co Cardiovalve
Chinese structural heart disease treatment company, Venus Medtech, has agreed to acquire Israeli heart valve treatment company, Cardiovalve, for $300 million. The deal includes an immediate payment of $150 million and a further $150 million contingent on regulatory milestones. Venus Medtech has also committed to invest an additional $100 million in Cardiovalve. Cardiovalve was founded in 2010 by Amir Gross, who will continue to lead the companys innovation under Venus Medtech.
AcquisitionInvestment
Israel's Peregrine Ventures raises $115 million for new med-tech fund
growth-positive
Edwards buys Israeli co Valtech Cardio for $1b
US company Edwards Lifesciences Corporation is acquiring Israeli valve repair device company Valtech Cardio Ltd. for $340 million in stock and cash, with the potential for up to $350 million in milestone payments over the next 10 years and $300 million more for Valtechs early-stage transseptal mitral valve replacement technology program. Valtech Cardio was founded in 2016 and has raised $70 million to date. The acquisition is expected to close in early 2017.
Acquisition
Peregrine Ventures Team
Boaz Lifschitz
Co-founder & Managing General Partner
Founder
David (Dudi) Eldar
CFO
Tal Carasso
Venture Partner & Director of Investor Relations
Lior Shahory
General Partner
Tsipi Gibor
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
Peregrine Ventures Internal
Recent Updates
Tal Carasso
· talc@peregrinevc.com · Manual · 2023-11-29 09:37:20.000000
Amit Alfasi
· amit@peregrinevc.com · Manual · 2024-03-07 12:14:38.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-10-25 15:53:15.000000
Amit Alfasi
· amit@peregrinevc.com · Manual · 2024-03-07 12:54:03.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-10-25 13:50:06.000000
Ortal Wein
· ortalw@sncentral.org · Automatic · 2023-03-21 12:40:26.000000
Ayelet Levi Shinebox
· ayeletlevis@sncentral.org · Manual · 2025-01-02 13:12:33.000000
Amit Alfasi
· amit@peregrinevc.com · Manual · 2024-03-07 12:38:27.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-10-25 13:57:13.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-10-24 12:14:11.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-10-25 15:54:00.000000
Tal Carasso
· talc@peregrinevc.com · Manual · 2023-03-15 22:39:18.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-11-29 09:19:36.000000
Amit Alfasi
· amit@peregrinevc.com · Manual · 2024-03-07 12:54:03.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-10-25 13:14:07.000000
Amit Alfasi
· amit@peregrinevc.com · Manual · 2024-03-07 12:43:23.000000
Tal Carasso
· talc@peregrinevc.com · Manual · 2023-11-29 09:37:23.000000
Tal Carasso
· talc@peregrinevc.com · Manual · 2023-11-29 09:37:20.000000
Amit Alfasi
· amit@peregrinevc.com · Manual · 2024-03-07 13:01:01.000000
Amit Alfasi
· amit@peregrinevc.com · Manual · 2024-03-07 12:54:03.000000
Amit Alfasi
· amit@peregrinevc.com · Manual · 2024-03-07 12:54:04.000000
Amit Alfasi
· amit@peregrinevc.com · Manual · 2024-03-07 13:08:33.000000
Amit Alfasi
· amit@peregrinevc.com · Manual · 2024-03-07 12:54:03.000000
Amit Alfasi
· amit@peregrinevc.com · Manual · 2024-03-07 13:11:08.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-10-25 13:50:06.000000
Tal Carasso
· talc@peregrinevc.com · Manual · 2023-11-29 09:37:22.000000
Amit Alfasi
· amit@peregrinevc.com · Manual · 2024-03-25 14:42:42.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-11-29 09:20:21.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-10-24 13:38:28.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2022-10-25 13:13:23.000000
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 56/100 |
| Missing | product stage, sector, number of employees, business model, tag line, funding rounds, markets, not claimed |
| BI Verification | Ortal Wein |
| Registrar ID | 513790196 |
| Crunchbase | peregrine-ventures |
| Phone | 972-3-6349990 |
| Creator | Ortal Wein |
| Creator email | ortalw@sncentral.org |
| Last updater | Ayelet Levi Shinebox |
| Updater email | ayeletlevis@sncentral.org |
| Last update | 2025-01-02T00:00:00.000Z |
| Created | 2022-10-24T00:00:00.000Z |